Skip to main content
. 2016 Oct 12;7(46):76087–76100. doi: 10.18632/oncotarget.12590

Figure 5. Effect of anakinra on the anti-tumor efficacy of erlotinib in erlotinib resistant (ER) and erlotinib-sensitive (ES) HNSCC cells in vivo.

Figure 5

ER-SQ20B A., ES-SQ20B B., ER-CAL 27 C. and ES-CAL 27 D. tumor bearing nude mice were treated with water (Con), erlotinib (Erl), anakinra (Ana) or erlotinib+anakinra (Ana+Erl) for 2-3 weeks. Tumor volumes were plotted against days since treatment initiation. Tumor growth graphs were interrupted at the time point where the mice (in any of the treatment groups) began to reach euthanasia criteria due to tumor size or ulcerating tumors. N = 6-11 mice per treatment group. Error bars represent ± standard error of the mean. *p<0.05, Πp<0.01, #p<0.001, ψp<0.0001.